Background
Adding
testosterone to hormonal therapy could improve sexual function and general
well-being among women during climacteric. We evaluated the effectiveness of
testosterone undecanoate on sexual function in postmenopausal women utilizing
the standardized questionnaire FSFI score.
Methods
Postmenopausal
women with sexual complaints and Female Sexual Function Index (FSFI) ≤ 26.5
were enrolled in to this randomized, double-blinded, placebo-controlled trial.
Participants were randomly assigned to 8-week treatment with either oral
testosterone undecanoate 40 mg or placebo twice weekly with daily oral
estrogen. The FSFI scores before and after treatment were compared to assess
any improvement of sexual function.
Results
Seventy
women were recruited of which each group had 35 participants. The baseline
characteristics and baseline FSFI scores were comparable between both groups.
After 8 weeks of treatment, the FSFI scores significantly improved in both
groups when compared to the baseline but the FSFI scores from the testosterone
group were significantly higher than in the placebo group post-treatment (28.6
± 3.6, 25.3 ± 6.7, respectively, p = 0.04). There was no difference in adverse
effect between the two groups.
Conclusions
The
twice weekly addition of testosterone undecanoate to daily oral estrogen was
associated with a significant improvement in sexual function among
postmenopausal women than the use of the estrogen alone.
Full article at:
By:
1Menopause Research Unit, Reproductive
Medicine Division, Department of Obstetrics and Gynecology, Faculty of
Medicine, Chulalongkorn University, Rama IV Road, Bangkok 10330, Thailand
2Endocrinology and Metabolism Unit,
Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University,
Rama IV Road, Bangkok 10330, Thailand
More at: https://twitter.com/hiv_insight
No comments:
Post a Comment